GEA
VRTX icon

Glen Eagle Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Glen Eagle Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.4K Sell
178
-2
-1% -$886 0.01% 367
2026
Q1 		$80.4K Buy
180
+176
+4,400% +$82.1K 0.01% 364
2025
Q4 		$1.81K Sell
4
-9
-69% -$3.88K ﹤0.01% 892
2025
Q3 		$5.09K Sell
13
-6
-32% -$2.51K ﹤0.01% 783
2025
Q2 		$8.46K Hold
19
– – ﹤0.01% 671
2025
Q1 		$9.21K Hold
19
– – ﹤0.01% 651
2024
Q4 		$7.65K Hold
19
– – ﹤0.01% 691
2024
Q3 		$8.84K Buy
19
+4
+27% +$1.92K ﹤0.01% 680
2024
Q2 		$7.03K Buy
+15
New +$6.51K ﹤0.01% 707
2023
Q1 		– Sell
-2
Closed -$578 – 1215
2022
Q4 		$578 Buy
+2
New +$610 ﹤0.01% 1064
2022
Q1 		– Sell
-20
Closed -$4.39K – 978
2021
Q4 		$4.39K Hold
20
– – ﹤0.01% 722
2021
Q3 		$3.63K Hold
20
– – ﹤0.01% 850
2021
Q2 		$4.03K Hold
20
– – ﹤0.01% 840
2021
Q1 		$4.3K Hold
20
– – ﹤0.01% 790
2020
Q4 		$4.73K Buy
+20
New +$4.59K ﹤0.01% 750

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Glen Eagle Advisors's VRTX Position: Q2 2026 in Review

Glen Eagle Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q2 2026, selling an estimated $886 and leaving 178 shares worth $88.4K. The position accounts for 0.01% of the portfolio, ranked #367.

Glen Eagle Advisors first reported a position in VRTX in Q4 2020 and has held it in 15 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Glen Eagle Advisors held 178 shares of Vertex Pharmaceuticals worth $88.4K as of Q2 2026.
  • Glen Eagle Advisors sold 2 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886.
  • Vertex Pharmaceuticals made up 0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #367 holding.
  • Glen Eagle Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.